Search research articles
Contact Us
Filters
Showing results (191-200 of 257) with videos related to
Page
of 26
Sort By:
Dermatology and Therapy
|
December 9, 2022
Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative
Jan Koren, Jo L W Lambert, Simon F Thomsen, et al.
The Journal of Investigative Dermatology
|
May 2, 2017
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The Journal of Investigative Dermatology
|
September 3, 2017
Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
Journal of the American Academy of Dermatology
|
November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)
Richard B Warren, Lars E French, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology
|
April 26, 2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Andrew Blauvelt, Richard G Langley, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials
April W Armstrong, Mark Lebwohl, Richard B Warren, et al.
The Journal of Investigative Dermatology
|
March 29, 2025
Blood Single-Cell Transcriptomic and Proteomic Signatures of Paradoxical Eczema in Patients with Psoriasis Treated with Biologics
Ali Al-Janabi, Paul Martin, Catherine Simpson, et al.
Journal of the American Academy of Dermatology
|
July 21, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
Andrew Blauvelt, Richard G Langley, Jean-Philippe Lacour, et al.
Annals of the Rheumatic Diseases
|
September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
The Journal of Investigative Dermatology
|
June 9, 2015
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B Warren, Catherine H Smith, Zenas Z N Yiu, et al.
Page
of 26
Search research articles
Search
Showing results (191-200 of 257) with videos related to
Sort By:
Page
of 26
Dermatology and Therapy
|
December 9, 2022
Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative
Jan Koren, Jo L W Lambert, Simon F Thomsen, et al.
The Journal of Investigative Dermatology
|
May 2, 2017
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
The Journal of Investigative Dermatology
|
September 3, 2017
Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Zarif K Jabbar-Lopez, Zenas Z N Yiu, Victoria Ward, et al.
Journal of the American Academy of Dermatology
|
November 11, 2023
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)
Richard B Warren, Lars E French, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology
|
April 26, 2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Andrew Blauvelt, Richard G Langley, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials
April W Armstrong, Mark Lebwohl, Richard B Warren, et al.
The Journal of Investigative Dermatology
|
March 29, 2025
Blood Single-Cell Transcriptomic and Proteomic Signatures of Paradoxical Eczema in Patients with Psoriasis Treated with Biologics
Ali Al-Janabi, Paul Martin, Catherine Simpson, et al.
Journal of the American Academy of Dermatology
|
July 21, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
Andrew Blauvelt, Richard G Langley, Jean-Philippe Lacour, et al.
Annals of the Rheumatic Diseases
|
September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
The Journal of Investigative Dermatology
|
June 9, 2015
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B Warren, Catherine H Smith, Zenas Z N Yiu, et al.
Page
of 26